Advertisement

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement

Jul

15

Today In Oncology

Gedatolisib Combinations Approved by FDA for HR-Positive/HER2-Negative Breast Cancer

FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors

American Cancer Society Reports Latest Global Cancer Statistics

Setmelanotide in Patients With Acquired Hypothalamic Obesity From Brain Tumors

Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy

Advertisement

© 2026 HSP News Service, L.L.C.